329946-26-1

Basic information

• Product Name: 6-BROMO-N-METHOXY-N-METHYLPYRIDINE-2-CARBOXAMIDE
• Synonyms: 6-BROMO-N-METHOXY-N-METHYLPYRIDINE-2-CARBOXAMIDE
• CAS NO: 329946-26-1
• Molecular Formula: C₈H₉BrN₂O₂
• Molecular Weight: 245.07
• Mol File: 329946-26-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-BROMO-N-METHOXY-N-METHYLPYRIDINE-2-CARBOXAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMO-N-METHOXY-N-METHYLPYRIDINE-2-CARBOXAMIDE(329946-26-1)
• EPA Substance Registry System: 6-BROMO-N-METHOXY-N-METHYLPYRIDINE-2-CARBOXAMIDE(329946-26-1)

Safety Data

• Hazardous Substances Data: 329946-26-1(Hazardous Substances Data)

Upstream product

• 21190-87-4 6-bromo-pyridine-2-carboxylic acid 
• 1117-97-1 N,0-dimethylhydroxylamine 
• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 

Relevant articles and documents

Diversification of 6-bromo-2-substituted Pyridine Derivatives via Suzuki-Miyaura Cross-Coupling

The functionalized pyridine ring is a ubiquitous moiety in numerous research areas including materials, natural products, as well as agrochemicals and is a strategic synthon for heteroaromatic synthetic method development. Pyridinyl ligand scaffolds are also frequently incorporated into the study of metal complexes for pharmaceutical applications or separation science. Convergent access to advanced synthons is critical to experimentally defining structure activity relationships and improvement of molecular performance in the aforementioned areas. The current work describes an efficient catalyst/ligand combination for accessing 2-acetyl- and 2-procarbonyl substituted pyridines via Suzuki-Miyaura cross-coupling with various organotrifluoroborates. Twenty examples are described with carbonyl and procarbonyl functional groups which afford subsequent access to diversified unsymmetric ketones. Substrate scope and limitation in addition to?a scale up experiment are reported.

Structure-based optimization of hydroxylactam as potent, cell-active inhibitors of lactate dehydrogenase

Structure-based design was utilized to optimize 6,6-diaryl substituted dihydropyrone and hydroxylactam to obtain inhibitors of lactate dehydrogenase (LDH) with low nanomolar biochemical and single-digit micromolar cellular potencies. Surprisingly the replacement of a phenyl with a pyridyl moiety in the chemical structure revealed a new binding mode for the inhibitors with subtle conformational change of the LDHA active site. This led to the identification of a potent, cell-active hydroxylactam inhibitor exhibiting an in vivo pharmacokinetic profile suitable for mouse tumor xenograft study.

LDHA ACTIVITY INHIBITORS

The invention provides compounds of formula (I), stereoisomers and pharmaceutically acceptable salts thereof: (I) wherein A1 to A4, R1 and RP are as defined herein. Such compounds are suitable for use in the treatment or prevention of diseases or conditions which are mediated by the activation of lactate dehydrogenase A (LDHA), for example cancer.

PIPERIDINE-DIONE DERIVATIVES FOR USE AS CONTRACEPTIVES

The invention relates to a method of reducing sperm motility or of contraception in a subject, said method comprising the step of administering to said subject an effective amount of a compound of formula (I), a stereoisomer, tautomer, pharmaceutically ac

LDHA ACTIVITY INHIBITORS

The invention provides compounds of formula (I), stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof: (I) wherein A1 to A6 and R1 to R4 are as defined herein. Such compounds are suit

IRAK4 INHIBITING AGENTS

Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.

METHOD OF CONTROLLING LACTATE PRODUCTION WITH PIPERDINE-DIONE DERIVATIVES

The invention provides novel compounds having the general formula: and tautomers and pharmaceutically acceptable salts thereof, wherein A1, A2, A3, A4, R1, R4, R5, R6, R7 and R8 are as defined herein, compositions including the compounds and methods of using the compounds.

PIPERIDINE-DIONE DERIVATIVES

The invention provides novel compounds having the general formula (I) and tautomers and pharmaceutically acceptable salts thereof, wherein A1, A2, A3, A4, R1, R4, R5, R6, R7 and R8 are as defined herein, compositions including the compounds and methods of using the compounds.

PHENYLALKANOIC ACID AND PHENYLOXYALKANOIC ACID DERIVATIVES AS HPPAR ACTIVATORS

The present invention provides a compound of formula (I):wherein:R1 and R2 are independently H or C1-3 alkyl;X represents a O or (CH2)n where n is 0, 1 or 2;R3and R4 independently represent H, C1-3 alkyl, -OCH3, -CF3, allyl, or halogen;X1 represents O, S, SO2, SO, or CH2;R5 and R6 independently represent hydrogen, C1-6 alkyl (including branched alkyl and optionally substituted by one or more halogens or C1-6alkoxy), or together with the carbon atom to which they are bonded form a 3-6 membered cycloalkyl ring;R7 represents a phenyl or a 6 membered heteroaryl group containing 1, 2 or 3 nitrogen atoms wherein the phenyl or heteroaryl group is substituted by 1, 2 or 3 moieties selected from the group consisting of halogen, C1-6 alkoxy, C1-6 alkyl, CF3, hydroxy, or phenyl (which may be optionally substituted by one or more C1-3 alkyl, -OC1-3 alkyl, CN, acetyl, hydroxy, halogen or CF3).